US3624216A - 8-substituted theophyllines as anti-inflammatory agents - Google Patents
8-substituted theophyllines as anti-inflammatory agents Download PDFInfo
- Publication number
- US3624216A US3624216A US49919A US3624216DA US3624216A US 3624216 A US3624216 A US 3624216A US 49919 A US49919 A US 49919A US 3624216D A US3624216D A US 3624216DA US 3624216 A US3624216 A US 3624216A
- Authority
- US
- United States
- Prior art keywords
- inflammatory agents
- substituted
- theophyllines
- theophylline
- substituted theophyllines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Definitions
- This invention relates to a method of treating inflammation in mammals and more particularly relates to the use of 8-substituted theophyllines as anti-inflammatory agents.
- C -C alkyl refers to straight and branched chain alkyls including n-propyl, iso-propyl, nbutyl, sec-butyl, n-pentyLand the like.
- the compounds are administered to patients in need of such treatment in dosages of from 5 to 100 mg./kg. daily either in single or divided doses. lt is preferred, however, that the anti-inflammatory agents be administered in divided doses, i.e., every 4 to 6 hours.
- the compounds can be administered in a variety of dosage forms comprising as an active ingredient at least one of the compounds useful in the practice of this invention in association vention include the following:
- the compounds useful in the practice of this invention are conveniently prepared by reacting 5,6- diamino-l,3-dimethyl-uracil (commercially available from Aldridge Chemical Co., Milwaukee, Wis.) with an acid of the formula wherein R is C C alkyl or cycloalkyl according to the following reaction scheme.
- the active agent may be the sole ingredient in the capsule.
- the preferred route of administration is the oral route.
- Representative compounds useful in the practice of this inl A method of relieving inflammation and the concommitant pain, fever, swelling, and tenderness in mammals by administering from 5 to l00 mg./kg. of a compound of the formula wherein R is Q, to C alkyl or cycloalkyl.
Abstract
A method of relieving inflammation and its concomittant swelling, tenderness and pain by administering therapeutically effective amounts of an 8-substituted theophylline to a patient in need of such treatment.
Description
United States Patent Herman Hal Stein Skokie;
Elizabeth Goodsell, Waukegan, both of II]. 49,919
June 25, 1970 Nov. 30, 1971 Abbott Laboratories North Chicago, Ill.
Inventors Appl. No. Filed Patented Assignee S-SUBSTITUTED THEOPHYLLINES AS ANTI- INFLAMMATORY AGENTS 3 Claims, No Drawings US. Cl 424/253 Quevauviller, Actualitis PharmacoL, 8:106- l52 1955) Primary ExaminerStanley J. Friedman Attorney-Robert L Niblack ABSTRACT: A method of relieving inflammation and its concomittant swelling, tenderness and pain by administering therapeutically effective amounts of an 8-substituted theophylline to a patient in need of such treatment.
8-SUBSTITUTED THEOPHYLLINES AS ANTI- INFLAMMATORY AGENTS DETAlLED DESCRIPTION OF THE INVENTION This invention relates to a method of treating inflammation in mammals and more particularly relates to the use of 8-substituted theophyllines as anti-inflammatory agents.
Numerous humans and animals are known to suffer from various rheumatic conditions involving inflammation, swelling, tenderness, decreased mobility, pain and fever. While there are a number of currently available anti-inflammatory agents which have been found to be effective in the symptomatic treatment of conditions such as rheumatoid arthritis, rheumatoid spondylitis, degenerative joint disease (osteoarthritis) of the hip,-and the like, such agents have a number of undesirable side effects. Thus, the search for improved anti-inflammatory agents continues.
Accordingly, it is a primary object of this invention to provide method for treating inflammation in mammalian patients.
Theophylline and various 8-substituted theophyllines have previously been reported as central nervous system stimulants and as diuretics. ISee, for example, Quevauviller, "Actualitis Pharmacol," 8: 106-52 (1955)]. It has been found that certain S-substituted theophylline derivatives of the formula wherein R is C to C alkyl or cycloalkyl, are effective, orally active anti-inflammatory agents when administered to mammals in need of such treatment in dosages of from S to I mgJkg. of body weight daily.
As used herein, the term C -C alkyl refers to straight and branched chain alkyls including n-propyl, iso-propyl, nbutyl, sec-butyl, n-pentyLand the like.
The anti-inflammatory activity of the 8-substituted theophyllines useful in the practice of this invention was established in the Rat and Mouse Paw Edema test carried out according to the method described by Winter et al., Proc. Soc. Exp. Biol. Med.,-"- lll:544 (l962) and L. Levy, Carrageenan Paw Edema in the Mouse, Life Sci., 8, p. l (I969).
In the practice of this invention the compounds are administered to patients in need of such treatment in dosages of from 5 to 100 mg./kg. daily either in single or divided doses. lt is preferred, however, that the anti-inflammatory agents be administered in divided doses, i.e., every 4 to 6 hours. The compounds can be administered in a variety of dosage forms comprising as an active ingredient at least one of the compounds useful in the practice of this invention in association vention include the following:
B-Cyclobutyltheophylline S-n-Pentyltheophylline 8-n-Propyltheophylline B-Cyclopropyltheophylline S-iso-Propyltheophylline S-n-Butylthcophylline H-sec-Butyltheophylline The 8-substituted theophyllines useful in the practice of this invention can be prepared according to the methods described by Hager et al., J. Am. Pharm. Associ," 43, 152 l954) and by Furst and Ebert, J. Chem. Ber.," 93, p. 99 (1960). Generally speaking, the compounds useful in the practice of this invention are conveniently prepared by reacting 5,6- diamino-l,3-dimethyl-uracil (commercially available from Aldridge Chemical Co., Milwaukee, Wis.) with an acid of the formula wherein R is C C alkyl or cycloalkyl according to the following reaction scheme.
CH; CH; 1 r: 0 NH, 2 A 0: NH,
I RC 2 1 Ha -N NH, H C-N No II R 0 0 1r lNaOH A ('33: N N l B I N 0 H We claim:
with a pharmaceutically acceptable carrier or diluent. How- I ever, in the case of filled capsules, for example, the active agent may be the sole ingredient in the capsule. The compounds exhibit both oral and parenteral activity, however, the preferred route of administration is the oral route.
Representative compounds useful in the practice of this inl. A method of relieving inflammation and the concommitant pain, fever, swelling, and tenderness in mammals by administering from 5 to l00 mg./kg. of a compound of the formula wherein R is Q, to C alkyl or cycloalkyl.
2. A method in accordance with claim 1 wherein the compound is 8-cyclobutyl theophylline.
3. A method in accordance with claim 1 wherein the compound is S-n-butyl theophylline.
Claims (2)
- 2. A method in accordance with claim 1 wherein the compound is 8-cyclobutyl theophylline.
- 3. A method in accordance with claim 1 wherein the compound is 8-n-butyl theophylline.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4991970A | 1970-06-25 | 1970-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3624216A true US3624216A (en) | 1971-11-30 |
Family
ID=21962452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US49919A Expired - Lifetime US3624216A (en) | 1970-06-25 | 1970-06-25 | 8-substituted theophyllines as anti-inflammatory agents |
Country Status (1)
Country | Link |
---|---|
US (1) | US3624216A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
EP0374808A2 (en) * | 1988-12-22 | 1990-06-27 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
US5068236A (en) * | 1989-03-06 | 1991-11-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
US5861405A (en) * | 1993-05-03 | 1999-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | S-substituted 1,3,7-trialkyl-xanthine derivatives |
WO2006116718A2 (en) | 2005-04-28 | 2006-11-02 | Proteus Biomedical, Inc. | Pharma-informatics system |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
US20090291972A1 (en) * | 2008-01-18 | 2009-11-26 | The Board Of Trustees Of The University Of Illinois | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer |
EP2147679A2 (en) | 2001-07-25 | 2010-01-27 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
WO2012044761A1 (en) | 2010-09-29 | 2012-04-05 | University Of North Carolina At Wilmington | Ladder-frame polyether conjugates |
EP4218718A2 (en) | 2009-05-06 | 2023-08-02 | Laboratory Skin Care, Inc. | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
-
1970
- 1970-06-25 US US49919A patent/US3624216A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
Quevauviller, Actualitis Pharmacol., 8:106 152 (1955) * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
US5532368A (en) * | 1988-12-22 | 1996-07-02 | Boehringer Ingelheim Gmbh | Xanthine derivatives with adenosine-antagonistic activity |
EP0374808A2 (en) * | 1988-12-22 | 1990-06-27 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
EP0374808A3 (en) * | 1988-12-22 | 1991-05-15 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
US5175291A (en) * | 1988-12-22 | 1992-12-29 | Boehringer Ingelheim Kg | Process for preparing 1,3-dipropyl-8-(3-oxocyclopentyl)-xanthine |
US5696124A (en) * | 1988-12-22 | 1997-12-09 | Boehringer Ingelheim Kg | Xanthine derivatives with adenosine-antagonistic activity |
US5068236A (en) * | 1989-03-06 | 1991-11-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
US5587378A (en) * | 1992-04-08 | 1996-12-24 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
US5861405A (en) * | 1993-05-03 | 1999-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | S-substituted 1,3,7-trialkyl-xanthine derivatives |
EP2147679A2 (en) | 2001-07-25 | 2010-01-27 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
WO2006116718A2 (en) | 2005-04-28 | 2006-11-02 | Proteus Biomedical, Inc. | Pharma-informatics system |
EP2392258A1 (en) | 2005-04-28 | 2011-12-07 | Proteus Biomedical, Inc. | Pharma-informatics system |
EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
US20090291972A1 (en) * | 2008-01-18 | 2009-11-26 | The Board Of Trustees Of The University Of Illinois | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
EP4218718A2 (en) | 2009-05-06 | 2023-08-02 | Laboratory Skin Care, Inc. | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
WO2012044761A1 (en) | 2010-09-29 | 2012-04-05 | University Of North Carolina At Wilmington | Ladder-frame polyether conjugates |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3624216A (en) | 8-substituted theophyllines as anti-inflammatory agents | |
KR850001883B1 (en) | Process for preparing crystalline benzothiazine dioxide salts | |
HUT47217A (en) | Process for producing pharmaceutical compositions containing indol derivatives as active components | |
US3666856A (en) | Treating immune response with amino purine derivatives | |
US3758684A (en) | Treating dna virus infections with amino purine derivatives | |
GB1363506A (en) | Process for the preparation of alpha-amino-penicillins and such penicillins and intermediates and pharmaceutical preparations | |
PT98007A (en) | METHOD FOR PREPARING AMINOBENZODIAZEPINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
US4081534A (en) | Amino purine nucleosides as autoimmune suppressant agents | |
CA2057734C (en) | Oxidized-type glutathione alkyl ester | |
US4241086A (en) | Method for treating rheumatism | |
JPH0134970B2 (en) | ||
US3624215A (en) | 8-substituted theophyllines as anti-anxiety agents | |
DK562488A (en) | PHARMACEUTICAL PREPARATION CONTAINING POLYMINE DERIVATIVES, AND SOME OF THESE POLYAMINE DERIVATIVES | |
US4053617A (en) | 2,1,3-benzothiadiazoles as myolonolytics | |
US3934018A (en) | 4,6-Dihydro-1,3-dimethyl-8-phenylpyrazolo[4,3-e] [1,4]diazepin-5-(1H)-one and derivatives as anti-inflammatory agents | |
EP0302263B1 (en) | Therapeutic composition for combatting aids | |
US4873223A (en) | Zinc salt of fructose-1,6-diphosphate | |
US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
KR20020007188A (en) | Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
US4038479A (en) | Amino purine derivatives | |
EP0407701A2 (en) | Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives | |
US4436732A (en) | Medicated compound for treating diseases infected by virus of the herpes group | |
US3067242A (en) | Di-(n, n-dimethyloctadecylamine) pamoate | |
JPH0572903B2 (en) | ||
US5475028A (en) | 2-aminoethanesulfonic acid zinc complex |